FY2024 Earnings Estimate for NuCana Issued By William Blair

NuCana plc (NASDAQ:NCNA) – Equities research analysts at William Blair increased their FY2024 EPS estimates for shares of NuCana in a report released on Monday, November 25th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($12.76) per share for the year, up from their previous estimate of ($15.75). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for NuCana’s current full-year earnings is ($12.46) per share. William Blair also issued estimates for NuCana’s Q4 2024 earnings at ($2.23) EPS, Q1 2025 earnings at ($2.23) EPS, Q2 2025 earnings at ($2.23) EPS, Q3 2025 earnings at ($2.23) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($9.57) EPS and FY2026 earnings at ($28.70) EPS.

Separately, Oppenheimer decreased their target price on shares of NuCana from $150.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 3rd.

NuCana Stock Up 0.8 %

NCNA stock opened at $1.30 on Thursday. NuCana has a 52-week low of $1.23 and a 52-week high of $19.41. The business has a fifty day moving average of $1.82 and a two-hundred day moving average of $3.06. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -0.12 and a beta of 1.03.

Institutional Trading of NuCana

A hedge fund recently bought a new stake in NuCana stock. Baillie Gifford & Co. acquired a new stake in NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 146,360 shares of the company’s stock, valued at approximately $378,000. Baillie Gifford & Co. owned 5.54% of NuCana at the end of the most recent quarter. 44.00% of the stock is owned by hedge funds and other institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.